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Glomerular monocytes predict worse outcomes after acute renal
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Glomerular monocytes predict worse outcomes after acute re-
nal allograft rejection independent of C4d status.
Background. Both peritubular capillary (PTC) C4d deposi-
tion and macrophage/monocyte (MO) infiltration in acute re-
jection (AR) have separately been shown to be associated with
reduced graft survival and recently were demonstrated to be
closely correlated in AR. Whether MO infiltration is an inde-
pendent predictor of graft outcome is uncertain.
Methods. All patients with biopsy-proven AR (over a 3-year
period) were included (N = 96). All biopsies (N = 121) were
graded according to the Banff 97 criteria and immunohisto-
chemically stained for C4d and MO (CD68). The primary out-
come was glomerular filtration rate (GFR) <30 mL/min 1-year
posttransplant as estimated by the Modified Diet in Renal Dis-
ease (MDRD) Formula. Secondary outcomes at 2 and 4 years’
posttransplant were also explored. A variety of clinical and
biopsy variables were statistically analyzed to establish univari-
ate predictors of graft outcome. Stepwise multivariate logistic
regression modeling was applied to determine independent pre-
dictors of outcomes.
Results. There was a close correlation between PTC C4d and
glomerular MO infiltration (P < 0.001). Univariate predictors
of primary outcome (GFR <30 mL/min 1-year posttransplant)
included mean glomerular MO count ≥1.0 MO/glomerulus
(P = 0.014), female sex (P = 0.02), higher peak (P = 0.005),
and pretransplant (P = 0.003) panel-reactive antibody lev-
els, cadaveric donor (P = 0.006), transplant glomerulitis (P =
0.004), and longer cold ischemic time (CIT) (P = 0.002). Mean
MO/glomerulus ≥1.0 [OR 10.3 (1.23, 87.1)], female sex [OR
5.27(1.31, 21.1)], and CIT [OR 1.14 (1.06, 1.25)] were identi-
fied as independent predictors of adverse graft outcome. Fur-
thermore, mean MO/glomerulus ≥1.0 independently predicted
poor renal function at 2 years [OR 3.89 (1.19, 12.70)] and 4 years
[OR 4.03 (1.22, 13.28)] posttransplant.
Conclusion. The results demonstrate that glomerular MO in-
filtration is an independent predictor of worse outcomes post-
transplant following acute renal allograft rejection.
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Acute renal allograft rejection is associated with
decreased graft survival [1–4]. Markers of antibody-
mediated (humoral) rejection (AHR) identify patients
at high immunologic risk who are more likely to have
a worse graft outcome [4, 5]. These markers include
peritubular capillary (PTC) staining for complement
fragment C4d, neutrophilic (PMN) infiltrate, arterial fib-
rinoid necrosis, vascular thrombosis, acute tubular injury,
infarction, and glomerulitis [6, 7]. In these studies, many
of the biopsies from patients with acute humoral rejec-
tion (AHR) also demonstrate the histologic features of
acute cellular rejection (ACR) as defined by the Banff
and Cooperative Clinical Trials in Transplantation crite-
ria (CCTT) [6–8].
Rejection episodes demonstrating the features of AHR
have been shown to carry a poor long-term prognosis
[6, 9–11] and are often resistant to conventional antire-
jection therapies [4, 8, 12, 13]. More recently, uncon-
ventional measures targeting suppression of recipient
humoral immunity, including plasmapheresis (with IVIG
administration or tacrolimus-mycophenolate rescue) or
immunoadsorption have been demonstrated to reverse
some of these rejection episodes, emphasizing the role of
AHR in allograft outcomes, even in biopsies also demon-
strating features of ACR [12, 14, 15].
Previous studies have demonstrated that glomerular
and interstitial monocyte/macrophage (MO) infiltration
in acute rejection have a detrimental effect on graft sur-
vival [16–26], and are associated with diffuse PTC C4d
deposition in acute rejection [27]. In view of the correla-
tion of PTC C4d deposition with reduced graft survival
[6, 9–12], it is uncertain whether MO infiltration is a sig-
nificant independent predictor of poor allograft outcome.
The primary goal of this retrospective study was to
test the independent prognostic value of MO infiltra-
tion in acute rejection on 1-year renal allograft function.
Longer term outcomes at 2 and 4 years’ posttransplant
were secondarily examined. The results demonstrate that
glomerular MO infiltration is an independent predictor
of a worse outcome at 1, 2, and 4 years’ posttransplant
following acute renal allograft rejection.
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METHODS
Patients
All renal transplant recipients in British Columbia with
biopsy-proven acute renal allograft rejection (Banff Cri-
teria 1997 [28]) between January 1, 1999 and December
31, 2001, in whom the rejection episode was within 12
months of transplant and sufficient tissue was available
for histologic and immunohistochemical analyses were
included. Of 106 potential subjects, 5 who died within the
first year of transplant and 5 with inadequate number of
glomeruli (<5) for glomerular MO count were excluded.
In total, 121 biopsies from 96 subjects were examined.
Recipient and donor data were compiled primarily
from the British Columbia Transplant Society renal trans-
plant database and the Patient Registration and Outcome
Management Information System (British Columbia).
Chart review was performed when specific information
was not available from the databases.
Histologic analyses
Renal biopsies were divided into 3 portions for light mi-
croscopy, electron microscopy, and immunohistochem-
istry. For light microscopy, tissue was fixed in either
B5 fixative (122 biopsies) and embedded in paraffin
or Karnovsky’s fixative (4 biopsies) and embedded in
polyglycol methacrylate. Sections embedded in paraf-
fin were cut at 2 lm and stained with hematoxylin-
eosin (H&E), periodic acid–Schiff (PAS), and periodic
acid-silver methenamine (PASM). Sections embedded in
polyglycol methacrylate were cut at 1 lm and stained with
H&E and PASM. The biopsies were examined by one of
the authors (A.B.M.).
Immunohistochemical analyses
The avidin-biotin peroxidase complex procedure for
antibody localization was used. Acetone-fixed sections
of snap-frozen renal tissue were stained with commer-
cially available mouse monoclonal antibodies specific for
complement split factor C4d (Quidel, San Diego, CA,
USA). Snap-frozen sections from biopsies of membra-
nous glomerulonephritis, which show strong glomeru-
lar staining for C4d served as positive controls for C4d.
B5-fixed paraffin-embedded sections were stained with
commercially available mouse monoclonal antibodies
specific for CD68 (a marker for MO) (Dako, Carpinteria,
CA, USA). For biopsies in which the histologic portion
had been embedded in polyglcol methacrylate, acetone-
fixed sections of snap-frozen renal tissue were stained
for CD68 with commercially available mouse monoclonal
antibodies (Dako). Lymph node tissue was used as pos-
itive controls for CD68. Negative controls consisted of
cases of thin basement membrane disease. Additional
control studies were performed by omitting the primary
monoclonal antibody in the staining procedure and by
using an irrelevant mouse monoclonal antibody as the
primary antibody.
The biopsies were evaluated by one of the authors
(A.B.M.). A biopsy was considered positive for C4d if
PTC showed either diffuse (>50% 0f PTC) or focal
(<50% of the PTC) circumferential staining for C4d. In
those biopsies with focal reactions, more than 10 PTC had
to show circumferential staining for C4d for a biopsy to
be scored as positive [29].
Clinical follow-up and monitoring
The primary outcome was glomerular filtration rate
(GFR) <30 mL/minute at 12 months’ posttransplant, in-
cluding graft failure, as estimated by the Modified Diet in
Renal Disease (MDRD) Formula [30], which has validity
in transplant recipients [31, 32]. This particular threshold
was chosen based on the current K-DOQI classification
of Chronic Kidney Disease (CKD) [33] and corresponds
to stage 4 CKD, in which progression to end-stage CKD
(stage 5) is greater, preparations are made for dialysis
or transplant, and the prevalence of renal-related comor-
bidities is high.
Secondary outcomes were MDRD GFR <30 mL/
minute at 24 and 48 months’ posttransplant. By
24 months, 2 subjects had been lost to follow-up, leav-
ing 94 subjects for analysis. Eighty-eight subjects had 48
complete months of posttransplant follow-up.
The following clinical parameters were assessed: (1) pa-
tient and donor ages at the time of renal transplantation;
(2) recipient gender; (3) graft type (living related, living
unrelated, cadaveric); (4) cold and warm ischemic times;
(5) serum panel-reactive antibody (PRA) levels, both his-
toric and at the time of transplantation; (6) number of
previous transplants; (7) number of HLA mismatches (0
to 6) between donor and recipient (A, B, and DR); (8)
presence or absence of delayed graft function defined as
a failure of serum creatinine (Cr) to fall below 50% of
initial Cr by 1 week posttransplant; (9) time to rejection;
and (10) baseline and follow-up serum Cr levels and pa-
tient weights sufficient for calculating MDRD GFR at all
time points of interest. Neither HLA antibody monitor-
ing nor flow cytometric crossmatching concurrent to AR
was routinely performed at our institution during the era
of this study.
Initial immunosuppression was achieved using a stan-
dard triple therapy regimen of methylprednisolone,
1 mg/kg/day for 3 to 5 days, then prednisone (0.7–1
mg/kg/day tapering to 0.3 mg/kg/day by 2 weeks’ post-
transplant and 0.15 mg/kg/day by 6 months) (all patients),
cyclosporine (CSA), 9.0 mg/kg/day adjusted for trough
levels 425 to 500 lg/mL for the first 30 days, then tapered
gradually to levels of 100 to 150 lg/L for long-term main-
tenance (70 patients), or tacrolimus (TAC), 0.12 to 0.15
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mg/kg/day adjusted for trough levels 10 to 15 lg/mL for
the first 30 days then tapered gradually to levels of 5 to
8 lg/mL for long-term maintenance (22 patients), and my-
cophenolate mofetil (MMF), 2000 mg/day (97 patients)
or azathioprine (AZA) 1 mg/kg/day (2 patients). Induc-
tion therapy was used in 11 patients at high immunologic
risk (PRA >30%, second or greater transplant) and con-
sisted of a 7-day course of therapy with antilymphocyte
antibodies (OKT3; Ortho Biotech, Raritan NJ, USA, or
ATG; Genzyme, Cambridge, MA, USA), 5 mg/day. All
rejection episodes were treated with methylprednisolone
for 3 to 6 days (total dose range 1500 mg to 4000 mg). Pa-
tients with Banff 97 grade 2A or greater or steroid resis-
tant rejections were treated with OKT3 5 mg/day or ATG
for 7 to 10 days. One C4d+ patient had plasma exchange
for 2 rejection episodes, with a total of 10 exchanges for
each episode, and IVIG following the plasma exchange
for the second episode. Another C4d+ patient with fea-
tures suggestive or AHR received IVIG alone.
Quantitative analysis
All biopsies were scored according to the Banff 97 cri-
teria to determine the type and grade of the rejection
reaction. MO and T cells were counted in all glomeruli
in each biopsy and expressed as the number of cells per
glomerulus. A threshold of greater than or equal to 1
MO per glomerulus was used to discriminate between
high and low glomerular monocyte counts. The number
of cortical interstitial (CI) MO per high power field (hpf)
(×40 objective with an object area diameter of 0.5 mm
and an area of 0.196 mm2) in each biopsy was determined
by counting the number of CI MO and cortical hpfs using
a high power objective (×40) and dividing the number of
cells by the number of cortical hpfs. For the quantitative
analyses at least 5 glomeruli were available for evalua-
tion.
Statistical analysis
Descriptive statistical values are presented as mean
± SD or as median: range depending on normality of
the underlying distribution. Continuous variables were
compared using the t test or the Wilcoxon rank sum test
where appropriate. Categorical variables were compared
using the v 2 test or Fisher exact test where appropriate.
A P value of less than 0.05 for two-sided univariate tests
was considered significant. Stepwise multivariate logis-
tic regression modeling was applied to the outcomes of
MDRD GFR ≤30 mL/minute at 12, 24, and 48 months’
posttransplant with P values for exclusion and inclusion
in the models 0.15 and 0.10, respectively. All potential bi-
ologic confounders were examined in the model (cadaver
donor, recipient sex, peak PRA, cold ischemic time, total
number of HLA mismatch, delayed graft function, Banff
grade, and C4d staining) and those variables that were
significant univariate predictors of each outcome were
forced into the model. Multiple threshold and categori-
cal models for defining high glomerular MO counts were
explored; the threshold of glomerular MO count of ≥1
was used as it provided the greatest discriminatory capa-
bility in the primary outcome multivariable model with
area under the ROC curve of 89%. Notably, results were
similar irrespective of the threshold used. Potential ef-
fect modification between glomerular MO count and all
model variables was individually tested for and none was
found. The most parsimonious model with the greatest
discriminatory value as determined by ROC analysis is
presented.
RESULTS
Renal biopsy findings
The 96 patients had 121 biopsies demonstrating vari-
ous grades of acute rejection. Eighty-five had 1 biopsy,
16 had 2 biopsies, and 1 patient had 4 biopsies. For those
with more than 1 biopsy the highest Banff 97 grade and
the highest glomerular and CI MO scores were used
for the statistical analysis. All but 15 biopsies had 10 or
more glomeruli. Twelve biopsies had 9 glomeruli, 2 had 8
glomeruli, and 1 had 7 glomeruli. All but 6 biopsies had
at least 2 large arteries for evaluation. One artery was
present in 3 of the biopsies, while 3 other biopsies did
not contain a large artery. In 31 patients the renal biopsy
was suspicious for acute rejection. For 37 and 27 patients
the highest Banff 97 grades were 1 (interstitial rejection
only) and 2 (vascular rejection), respectively. One patient
showed severe acute vascular rejection (Banff 97 grade
3). For analytical purposes this patient was grouped with
those showing less severe vascular rejection (Banff 97
grade 2). Transplant glomerulitis, expressed in this study
as Banff 97 Classification g score ≥1.0 [28], was noted
in 31 biopsies. None of the biopsies examined showed
chronic allograft nephropathy.
PTC C4d staining was observed in at least 1 biopsy from
27 patients (Table 1). This was diffuse in 16 and focal in
11. All biopsies exhibited varying degrees of glomerular,
arterial, and arteriolar reaction for C4d.
Glomerular MO infiltration (Fig. 1) was observed in
at least 1 of the biopsies from 67 patients. Forty-four
of these biopsies had an MO/glomerulus (MO/Glom)
score of <1.0 (mean 0.43 ± 0.27 MO/Glom; range 0.1–0.9
MO/Glom), while 23 showed 1 or more MO/Glom (mean
3.5 ± 2.0 MO/Glom; range 1.1–8.4 MO/Glom). Varying
numbers of CI MO were present in all of the biopsies
(mean 11.9 ± 11.0 MO/hpf; range 0.5–66.6 MO/hpf).
Patient and clinical characteristics
The detailed general characteristics of the entire cohort
are presented in Table 1. The male:female ratio was 58:38.
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Table 1. Patient population characteristics
Patients with <1
All patients MO/glomerulus ≥1 MO/glomerulus
Variable a (N = 96) (N = 73) (N = 23) P value
Demographics
Sex (N female)% 38 (40.0) 24 (32.9) 14 (60.9) 0.017
Mean recipient age years 45.2 ± 12.4 44.6 ± 12.2 47.1 ± 12.9 0.38
Mean donor age years 40.0 ± 15.0 39.3 ± 13.5 42.5 ± 19.0 0.44
Previous kidney transplant N (%) 0.13
0 79 (82.3) 63 (86.3) 16 (69.6)
1 15 (15.6) 9 (12.3) 6 (26.1)
≥2 2 (2.1) 1 (1.4) 1 (4.3)
Peak PRA N (%) 0.004
0% 77 (80.2) 64 (87.7) 13 (56.5)
1–29% 11 (11.5) 6 (8.2) 5 (21.7)
≥30% 8 (8.3) 3 (4.1) 5 (21.7)
Pretransplant PRA N (%) 0.03
0% 82 (85.4) 66 (90.4) 16 (69.6)
1–29% 9 (9.4) 5 (6.9) 4 (17.4)
≥30% 5 (5.2) 2 (2.7) 3 (13.0)
Transplant factors
Donor type N (%) 0.16
Cadaveric 40 (41.6) 27 (37.0) 13 (56.5)
LUD 25 (26.0) 19 (26.0) 6 (26.1)
LRD 31 (32.3) 27 (37.0) 4 (17.4)
Mean number of donor-recipient HLA matches 3.60 ± 1.28 3.51 ± 1.27 3.91 ± 1.31 0.19
Cold ischemic time hours 3.58: 1.45–28.0 3.43: 1.45–27.9 7.72: 2.5–24.0 0.05
Delayed graft function N (%) 29 (30.2) 18 (24.7) 11 (47.8) 0.07
Immunosuppression N (%)
CsA 32 (33.3) 24 (32.9) 8 (34.8) 1.0
Tacrolimus 64 (66.7) 49 (67.1) 15 (65.2)
MMF 89 (92.7) 67 (91.8) 22 (95.7) 1.0
Azathioprine 5 (5.21) 4 (5.5) 1 (4.4)
OKT3/ATG therapy N 16 (16.7) 12 (16.4) 4 (17.4) 0.76
OKT3/ATG induction N 4 (3.1) 1 (1.37) 2 (8.7) 0.14
CNIb level at time of rejection N (%) 0.73
Low 49 (51.0) 38 (52.1) 11 (48.8)
Appropriate 31 (32.3) 22 (30.1) 9 (39.1)
High 16 (16.7) 13 (17.8) 3 (13.0)
Rejection
Time to acute rejection days 13: 3–364 14: 3–364 11: 5–187 0.84
Cr at time of rejection lmol/L 239: 117–856 234: 117–856 256: 155–644 0.36
Increase in Cr from baseline lmol/L 49: 10–509 48:10–509 50: 10–274 0.53
(N = 74 achieved baseline Cr prior to rejection)
% change in Cr from baseline 35.6: 6.4–213 36.8: 6.4–213 36.6: 6.8–170 0.74
Banff class N (%) 0.38
Suspicious 31 (32.3) 22 (30.1) 9 (39.1)
I 37 (38.5) 31 (42.5) 6 (26.1)
II 28 (29.2) 20 (27.4) 8 (34.8)
C4d staining N (%) <0.001
Negative 69 (71.9) 65 (89.0) 4 (17.4)
Focal 11 (11.5) 7 (9.6) 4 (17.4)
Diffuse 16 (16.7) 1 (1.4) 15 (65.2)
Transplant glomerulitisc N (%) <0.001
g score 0 65 (67.7) 60 (82.2) 5 (21.7)
1 17 (17.7) 7 (9.6) 10 (43.5)
2 7 (7.3) 2 (2.7) 5 (21.7)
3 7 (7.3) 4 (5.5) 3 (13.0)
CI MO/hpf d 8.4: 0.5–66.6 7.3:0.5–66.6 12.3:0.7–36.0 0.11
Clinical outcomes
MDRD GFR <30 mL/min 12 months’ posttransplant N (%) 17 (17.7) 9 (12.3) 8 (34.8) 0.025
MDRD GFR <30 mL/min 24 months’ posttransplant N (%) 19 (16.2) 9 (12.5) 10 (45.5) 0.001
(N = 94 available)
MDRD GFR <30 mL/min 48 months’ posttransplant N (%) 23 (26.1) 13 (18.6) 10 (55.5) 0.005
(N = 88 available)
% decrease in Cr 2 weeks’ postrejection 15.8: 74.6–1026 19.2: 74.6–793 6.7: 76.3–1026 0.07
Graft failure at 12 months N (%) 8 (7.9) 3 (4.1) 5 (21.7) 0.018
aContinuous variables expressed as mean ± SD or median:range as indicated.
bCNI is calcineurin inhibitor.
cTransplant glomerulitis expressed as g score ≥1.0 (Banff 97 classification).
dCI MO/hpf is cortical interstitial monocytes per high-power field.
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Fig. 1. Immunohistochemical demonstration of CD68+ cells. The
glomerulus contains a number of CD68+ cells, some of which are indi-
cated by arrows (×250).
The mean recipient age was 45.2±12.4 years (range 22–79
years). The age range of the donors was 3 to 67 years, with
a mean of 40.0 ± 15.0 years. Seventeen patients had a pre-
vious transplant. A peak PRA ≥30% (highest on record)
was noted in 8 patients. Five patients had an immediate
pretransplant PRA ≥30%. Forty patients received a ca-
daveric allograft, while 56 obtained a living donor graft
(25 living unrelated, 31 living related). The mean num-
ber of HLA donor-recipient mismatches was 3.60 ± 1.28.
Cold ischemic time (CIT) varied from 1.45 hours to 28.0
hours with a median of 3.58 hours. Delayed graft function
occurred in 29 patients. CSA was given to 32 patients,
while 64 received TAC. MMF was used in 89 cases, while
5 patients received AZA. Sixteen patients were treated
with antilymphocyte antibodies for rejection. Calcineurin
inhibitor levels at the time of rejection were low in 49 pa-
tients, high in 19, and within the therapeutic range in 31.
The time to rejection ranged from 3 to 364 days post-
transplantation with a median of 13 days. The median
magnitude of the rise in Cr at the time of rejection from
baseline values was 49 lmol/L (range 10.0–509 lmol/L).
Seventeen patients had a MDRD GFR <30 mL/min
at 1 year posttransplant, including 8 experiencing graft
failure. The median time to graft failure was 105 days with
a range of 21 to 311 days. An additional 2 patients had an
MDRD <30 mL/min by 24 months and 3 more patients
developed an MDRD <30 mL/min by 48 months.
Comparison of high and low glomerular monocyte groups
The patients were divided into 2 groups according
to level of glomerular monocyte infiltration—those with
mean number of MO/glomerulus ≥1.0 (high MO group)
and those with <1.0 MO/glomerulus (low MO group).
The general characteristics and comparisons between the
2 groups are also presented in Table 1. There were pro-
portionately more women in the high MO group (61%
vs. 32.9%, P = 0.017). Twenty-one percent of subjects in
the high MO group had peak PRA ≥30% compared with
only 4.1% in the low MO group and, similarly, 13% of
the high MO group had high PRA immediately prior to
transplant compared with only 2.7% in the low MO group
(P = 0.004 and 0.03, respectively). Longer CIT and, re-
lated to this, a higher incidence of delayed graft function
were seen in the high MO group (P = 0.05 and 0.07, re-
spectively) as was a poorer response to therapy as defined
by percent change in Cr 2 weeks’ postrejection, although
this did not reach statistical significance (P = 0.07). Num-
ber of previous transplants, cadaveric versus living donor,
number of HLA mismatches between donor and recip-
ient, and type and level of immunosuppression was not
significantly different between the 2 groups. In addition,
median time to acute rejection was similar in both groups,
as was the mean serum creatinine at the time of rejection
and distribution of Banff 97 grades.
Glomerular monocytes and pathology findings
Banff 97 classification did not correlate with glomeru-
lar MO count. Transplant glomerulitis expressed as Banff
97 g score ≥1.0 was significantly more prevalent in the
high MO group (78.2%) than in the low MO group
(17.8%). Higher median CI MO counts were seen in the
high MO group (12.3 vs. 7.3), but this difference did not
reach statistical significance (P = 0.11).
Glomerular monocytes and C4d staining
The presence of glomerular MO is strongly corre-
lated with positive staining for C4d. Eighty-three percent
(83%)of high MO biopsies also were C4d positive, while
89% of low MO biopsies were C4d negative (P < 0.001)
(Table 2). The strong correlation was maintained in those
subjects with the primary outcome of interest (P = 0.027)
(Table 2), as well as those with better graft function at
1 year (P < 0.001) (data not shown). Furthermore,
the association between these 2 pathologic markers is
equally strong in both Suspicious/class I rejections and
class II rejections (P < 0.001 and = 0.006, respectively)
(Table 2).
Outcome
Poor allograft function at 1 year [GFR (MDRD)
<30 mL/min] was predicted by the glomerular mono-
cyte count. A percentage of subjects (34.8%) with ≥1.0
MO/glomerulus achieved this primary outcome, com-
pared with 12.3% of subjects in the low MO group (P =
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Table 2. Association of glomerular monocytes with C4d staining
C4d C4d
All subjects (N = 96) positive negative
≥1 MO/glomerulus 19 4
<1 MO/glomerulus 8 65 P < 0.001
Subjects with MDRD GFR
<30 mL/min 12 months’
posttransplant (N = 17)
≥1 MO/glomerulus 5 3
<1 MO/glomerulus 1 8 P = 0.027
Subjects with Banff suspicious
or class I rejection (N = 68)
≥1 MO/glomerulus 13 2
<1 MO/glomerulus 4 49 P < 0.001
Subjects with Banff class II
rejection (N = 28)
≥1 MO/glomerulus 6 2
<1 MO/glomerulus 4 16 P = 0.006
0.025) (Table 1). Additional univariate predictors of the
primary outcome are presented in Table 3. Higher peak
PRA (P = 0.005), higher pretransplant PRA (P = 0.003),
cadaveric donor (P = 0.006), longer CIT (P = 0.002), fe-
male gender (P = 0.02), and g score (P = 0.004) were all
associated with adverse outcomes. Stepwise forward lo-
gistic regression modeling was applied to the primary out-
come, adjusting for all significant univariate predictors,
as well as potentially important biologic confounders.
Higher glomerular MO count [OR 10.3 (1.23, 87.1)], fe-
male sex [OR 5.27 (1.31, 21.1)], and longer cold ischemic
time [OR 1.14 (1.06, 1.25)] independently predicted ad-
verse 1-year allograft outcome (Table 4).
Transplant glomerulitis was a significant predictor of
primary outcome at 1 year (Table 3). Although there was
no association between C4d staining and 1-year outcome
(Table 3), 47.8% of those with poor outcome at 24 and
48 months had positive PTC staining for C4d compared
to 19.7% of other subjects (P = 0.011, data not shown).
In addition, all significant univariate predictors of the
primary outcome were predictive of 24- and 48-month
outcomes. Stepwise forward logistic regression model-
ing was applied to these secondary outcomes, and high
glomerular MO count remained independently predic-
tive of 24-month [OR 3.89 (1.19, 12.70)] and 48-month
[OR 4.03 (1.22, 13.28)] outcomes. Peak PRA was also
independently predictive of outcome at 24 months [OR
2.84 (1.27, 6.34)] and 48 months [OR 3.40 (1.37, 8.42)]
(Table 4).
In both C4d positive and C4d negative subjects, sub-
jects with higher glomerular monocyte counts have a
greater prevalence of poor 1-year allograft function
(P = 0.008) (Table 5). Among C4d positive subjects,
26.3% of subjects with high glomerular MO counts
achieved the primary outcome, compared with 12.5% of
those with low glomerular MO counts. With negative C4d
staining, 75% of high MO subjects achieved the primary
outcome versus 12.3% of those with low MO biopsies.
DISCUSSION
The results of this retrospective study establish the
association between the presence of glomerular MO in
acute rejection biopsies and reduced renal allograft sur-
vival 1, 2, and 4 years’ posttransplant independent of
other known predictors of adverse outcome, including
histologic type (Banff 97 grade) and PTC C4d status. The
occurrence of graft failure at all time points, and slower
recovery from acute rejection, was also greater in the high
MO group. The results of the present study are consis-
tent with previous demonstrations of the adverse effect
by glomerular MO on graft outcome [17, 18, 26].
The present investigation failed to find a significant as-
sociation between level of glomerular monocyte infiltra-
tion and Banff 97 grade. One previous study noted that
the highest numbers of glomerular MO were found in
cases of vascular rejection [26]. In addition, the results of
another study suggested, albeit indirectly, a relationship
between transplant glomerulitis, previously shown to be
due to glomerular accumulation of MO and T lympho-
cytes [27, 34, 35] and vascular rejection [29]. However,
Harry et al did not note any correlation between glomeru-
lar MO infiltration and any particular biopsy change [17].
Differences in patient population and treatment may ac-
count for the discrepancy in the results.
The results of the present investigation confirm and
extend the previously reported association between
glomerular MO infiltration and PTC C4d deposition [27].
In view of this association and the results of previous
studies [6, 9–11], especially the one from our institution
[9], the failure to demonstrate an independent detrimen-
tal effect of PTC C4d on graft outcome was unexpected.
The previous investigation from our laboratory involved
biopsies of acute rejection done between July 1, 1995 and
December 31, 1997 [9], whereas the present retrospective
study looked at patients with biopsies done between Jan-
uary 1, 1999 and December 31, 2001, during which time
all renal allograft biopsies were immunostained for C4d,
there was an increasing awareness of the significance of
PTC C4d staining, and there was increased use of both
TAC and MMF. Additionally, glomerular MO was not as-
sessed in the previous study [9]. This may account in part
for the differences in results with respect to the predictive
value of PTC C4d deposition. PTC C4d deposition was
univariately predictive of longer-term outcomes; whether
a significant independent deleterious effect of PTC C4d
deposition on graft outcome over even longer time pe-
riods will be demonstrated is uncertain. Finally, in this
regard, the results of the present investigation are con-
sistent with those of another study, which did not show
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Table 3. Univariate predictors of primary outcome
Group with MDRD GFR ≥30 Group with MDRD GFR <30
at 12 months’ posttransplant at 12 months’ posttransplant
Variablea (N = 79) (N = 17) P value
Demographics
Sex N female (%) 27 (31.2) 11 (64.7) 0.02
Mean recipient age years 44.5 ± 11.7 48.1 ± 15.3 0.18
Previous kidney transplant N (%) 0.16
0 67 (84.8) 12 (70.6)
1 11 (13.9) 4 (23.5)
≥2 1 (1.3) 1 (5.9)
Peak PRA N (%) 0.005
0% 67 (84.8) 10 (58.8)
1–29% 9 (11.4) 2 (11.8)
≥30% 3 (3.8) 5 (29.4)
Pretransplant PRA N (%) 0.003
0% 71 (89.9) 11 (64.7)
1–29% 7 (8.9) 2 (11.8)
≥30% 1 (1.2) 4 (23.5)
Transplant factors
Donor type N (%) 0.006
Cadaveric 27 (34.2) 13 (76.5)
LUD 24 (30.4) 1 (5.9)
LRD 28 (35.4) 3 (17.6)
Mean number of donor-recipient HLA matches 3.58 ± 1.22 3.70 ± 1.57 0.72
Cold ischemic time hours 3.3: 1.45–28.0 11.9: 3.3–25.2 0.002
Delayed graft function N (%) 22 (27.8) 7 (41.2) 0.278
Immunosuppression N (%)
CsA 26 (32.9) 6 (35.3) 1.0
Tacrolimus 53 (67.1) 11 (64.7)
MMF 73 (92.4) 16 (94.1) 0.23
Azathioprine 5 (6.3) 0 (0.0)
OKT3/ATG therapy 14 (17.7) 2 (11.8) 0.46
OKT3/ATG induction 2 (2.5) 2 (11.8) 0.13
CNIb level at time of rejection N (%) 0.77
Low 39 (49.4) 10 (58.8)
Appropriate 27 (34.2) 4 (23.5)
High 13 (16.5) 3 (17.6)
Rejection
Time to acute rejection days 11: 3–364 21: 7–356 0.17
% change in Cr from baseline 30.0: 6.4–213 46.2: 11.0–108 0.07
Mean Cr at time of rejection lmol/L 273 ± 149 333 ± 158 0.15
Banff class N (%) 0.68
Suspicious 25 (31.7) 6 (35.3)
I 32 (40.5) 5 (29.4)
II 22 (27.8) 6 (35.3)
C4d staining N (%) 0.69
Negative 58 (73.4) 11 (64.7)
Focal 9 (11.4) 2 (11.8)
Diffuse 12 (15.2) 4 (23.5)
≥1 MO/glomerulus N (%) 15 (19.0) 8 (47.1) 0.014
Transplant glomerulitisc N (%) 0.004
g score 0 59 (74.7) 6 (35.3)
1 12 (15.2) 5 (29.4)
2 5 (6.3) 2 (11.8)
3 3 (3.8) 4 (23.5)
4CI MO/hpf 8.1: 0.5–37.5 11.1: 0.7–66.6 0.38
aContinuous variables expressed as mean ± SD or median:range as indicated.
bCNI is calcineurin inhibitor.
cTransplant glomerulitis expressed as g score ≥1.0 (Banff 97 classification).
dCI/MOhpf is cortical interstitial monocytes per high-power field.
a significant difference between C4d positive and C4d
negative patients with acute rejection [29].
As transplant glomerulitis is associated with high
glomerular MO, it is tempting to use the former as a sur-
rogate for the latter. However, some caution is required
as transplant glomerulitis is often the result of glomerular
infiltration by both MO and T cells [27] and, in a number
of cases, especially in those biopsies that are PTC C4d
negative, the predominant infiltrating cell is the T cell
(with few MO) [36].
Unlike glomerular MO number, the level of CI MO
did not correlate with graft outcome at 1 year (data not
Tinckam et al: Glomerular monocytes predict rejection outcome 1873
Table 4. Results of stepwise multivariate logistic regression model
Variable OR 95% CI P value
Primary outcome of MDRD
GFR ≤30 mL/min at
1 year posttransplant
≥1 MO/glomerulus 10.3 [1.23, 87.1] 0.032
Female sex 5.27 [1.31, 21.1] 0.019
Cold ischemic time hours 1.14 [1.06, 1.25] 0.001
MDRD GFR ≤30 mL/min
at 2 years’ posttransplant
(N = 94)
≥1 MO/glomerulus 3.89 [1.19, 12.70] 0.025
Peak PRA 2.84 [1.27, 6.34] 0.011
MDRD GFR ≤30 mL/min
at 4 years’ posttransplant
(N = 88)
≥1 MO/glomerulus 4.03 [1.22, 13.28] 0.022
Peak PRA 3.40 [1.37, 8.42] 0.008
Table 5. Percent of subjects with the primary outcome in groups
defined by glomerular MO count and C4d staining
C4d positive C4d negative
≥1 MO/glomerulus 26.3% (5/19) 75.0% (3/4)
<1 MO/glomerulus 12.5% (1/8) 12.3% (8/65) P = 0.008
shown). Several previous studies have shown an associa-
tion between extent of CI MO infiltration and poor graft
survival [16, 19–21, 37]. Differences in patient popula-
tion, immunosuppression, and treatment of acute rejec-
tion may account for this discrepancy.
CONCLUSION
Predictors of the primary outcome by univariate
analysis included glomerular MO infiltration (≥1 MO/
glomerulus), female sex, peak and pretransplant PRA,
cadaveric donor, transplant glomerulitis, and longer cold
ischemic times. When adjusted for univariate predictors
of the primary outcome, as well as other clinical variables
considered to be prognostically significant (including de-
layed graft function [38, 39], number of HLA mismatches
[40, 41], calcineurin inhibitor level, and C4d staining [9]),
glomerular MO count ≥1 MO per glomerulus, longer
CIT, and female sex remained independent predictors
of adverse 1-year allograft function after acute rejection.
In addition, glomerular MO count ≥1 MO per glomeru-
lus in AR was independently predictive of poor allograft
function as far as 48 months’ posttransplant.
ACKNOWLEDGMENTS
K.T. is supported by a Canadian Institutes of Health Research
Fellowship, the Clinician Investigator Program (University of British
Columbia), and the Scholars in Clinical Science Program (Harvard
Medical School, K30 Curriculum Award HL04095-06). This study was
presented in part at the American Society of Nephrology Meeting,
Philadelphia, PA, October 30–November 4, 2002. We thank Linda
Hughes, Jasbir Gill, and Lee Cross for their excellent technical assis-
tance.
Reprint requests to Dr. Alex Magil, St. Paul’s Hospital, 1081 Burrard
Street, Vancouver, BC V6Z 1Y6 Canada.
E-mail: amagil@providencehealth.bc.ca
REFERENCES
1. TESI RJ, ELKHAMMAS EA, HENRY ML, et al: Acute rejection episodes:
Best predictor of long-term primary cadaveric renal transplant sur-
vival. Transplant Proc 25:901–902, 1993
2. COSIO FG, PELLETIER RP, SEDMAK DD, et al: Renal allograft survival
following acute rejection correlates with blood pressure levels and
histopathology. Kidney Int 56:1912–1919, 1999
3. HALLORAN PF, WADGYMAR A, RITCHIE S, et al: The significance of
the anti-class I antibody response. I. Clinical and pathologic features
of anti-class I-mediated rejection. Transplantation 49:85–91, 1990
4. COLLINS AB, SCHNEEBERGER EE, PASCUAL MA, et al: Complement
activation in acute humoral renal allograft rejection: Diagnostic
significance of C4d deposits in peritubular capillaries. J Am Soc
Nephrol 10:2208–2214, 1999
5. FEUCHT HE, FELBER E, GOKEL MJ, et al: Vascular deposition of
complement-split products in kidney allografts with cell-mediated
rejection. Clin Exp Immunol 86:464–470, 1991
6. MAUIYYEDI S, CRESPO M, COLLINS AB, et al: Acute humoral rejection
in kidney transplantation. II. Morphology, immunopathology, and
pathologic classification. J Am Soc Nephrol 13:779–787, 2002
7. TRPKOV K, CAMPBELL P, PAZDERKA F et al: Pathologic features of
acute renal allograft rejection associated with donor-specific an-
tibody: Analysis using the Banff grading schema. Transplantation
61:1586–1592, 1996
8. HALLORAN PF, SCHLAUT J, SOLEZ K, SRINIVASA NS: The significance
of the anti-class I response. II. Clinical and pathologic features
of renal transplants with anti-class I-like antibody. Transplantation
53:550–555, 1992
9. HERZENBERG AM, GILL JS, DJURDJEV O, MAGIL AB: C4d deposition
in acute rejection: An independent long-term prognostic factor. J
Am Soc Nephrol 13:234–241, 2002
10. BOHMIG GA, EXNER M, HABICHT A, et al: Capillary C4d deposition
in kidney allografts: A specific marker of alloantibody-dependent
graft injury. J Am Soc Nephrol 13:1091–1099, 2002
11. REGELE H, EXNER M, WATSCHINGER B, et al: Endothelial C4d depo-
sition is associated with inferior kidney allograft outcome indepen-
dently of cellular rejection. Nephrol Dial Transplant 16:2058–2066,
2001
12. PASCUAL M, SAIDMAN S, TOLKOFF-RUBIN N, et al: Plasma exchange
and tacrolimus-mycophenolate rescue for acute humoral rejection
in kidney transplantation. Transplantation 66:1460–1464, 1998
13. CRESPO M, PASCUAL M, TOLKOFF-RUBIN N, et al: Acute humoral re-
jection in renal allograft recipients. I. Incidence, serology and clinical
characteristics. Transplantation 71:652–658, 2001
14. THERUVATH TP, SAIDMAN SL, MAUIYYEDI S, et al: Control of an-
tidonor antibody production with tacrolimus and mycophenolate
mofetil in renal allograft recipients with chronic rejection. Trans-
plantation 72:77–83, 2001
15. BOHMIG GA, REGELE H, EXNER M, et al: C4d-positive acute humoral
renal allograft rejection: Effective treatment by immunoadsorption.
J Am Soc Nephrol 12:2482–2489, 2001
16. HAYRY P, VON WILLEBRAND E: Monitoring of human renal allograft
rejection with fine-needle aspiration cytology. Scand J Immunol
13:87–97, 1981
17. HARRY TR, COLES GA, DAVIES M, et al: The significance of mono-
cytes in glomeruli of human renal transplants. Transplantation
37:70–73, 1984
18. OM A, BAQUERO A, RAJA R, et al: The prognostic significance of the
presence of monocytes in glomeruli of renal transplant allografts.
Transplant Proc 19:1618–1622, 1987
19. BURKHARD K, HOFMANN GO, BO¨SNECKER A, et al: Early infiltration
of renal allografts with 27E10-positive macrophages and graft out-
come. Transpl Int 7 Suppl 1:S577–579, 1994
20. RAMOS EL, BARRI YM, CROKER BP, et al: Thromboxane synthase
1874 Tinckam et al: Glomerular monocytes predict rejection outcome
expression in renal transplant patients with rejection. Transplanta-
tion 59:490–494, 1995
21. CROKER BP, CLAPP WL, ABU SHAMAT AR, et al: Macrophages and
chronic renal allograft nephropathy. Kidney Int 57(Suppl):S42–49,
1996
22. GRIMM PC, MCKENNA R, NICKERSON P, et al: Clinical rejection is
distinguished from subclinical rejection by increased infiltration by
a population of activated macrophages. J Am Soc Nephrol 10:1582–
1589, 1999
23. PILMORE HL, PAINTER DM, BISHOP GA, et al: Early up-regulation of
macrophages and myofibroblasts: A new marker for development
of chronic renal allograft rejection. Transplantation 69:2658–2662,
2000
24. O¨ZDEMIR BH, O¨ZDEMIR FN, GU¨NGEN Y, HABERAL M: Role of
macrophages and lymphocytes in the induction of neovascular-
ization in renal allograft rejection. Am J Kidney Dis 39:347–353,
2002
25. BURKHARDT K, BOSNECKER A, HILLEBRAND G, et al: MRP8/14-
positive macrophages as early acute cellular rejection markers, and
soluble MRP8/14 and increased expression of adhesion molecules
following renal transplantation. Transplant Proc 27:890–891, 1995
26. O¨ZDEMIR BH, DEMIRHAN B, GU¨NGEN Y: The presence and prog-
nostic importance of glomerular macrophage infiltration in renal
allografts. Nephron 90:442–446, 2002
27. MAGIL AB, TINCKAM K: Monocytes and peritubular capillary C4d
deposition in acute renal allograft rejection. Kidney Int 63:1888–
1893, 2003
28. RACUSEN LC, SOLEZ K, COLVIN RB, et al: The Banff 97 working
classification of renal allograft pathology. Kidney Int 55:713–723,
1999
29. NICKELEIT V, ZEILER M, GUDAT F, et al: Detection of the comple-
ment degradation product C4d in renal allografts: Diagnostic and
therapeutic implications. J Am Soc Nephrol 13:242–251, 2002
30. LEVEY AS, BOSCH JP, LEWIS JB, et al: A more accurate method to
estimate glomerular filtration rate from serum creatinine: A new
prediction equation. Modification of Diet in Renal Disease Study
Group. Ann Intern Med 130:461–470, 1999
31. RODRIGO E, FERNANDEZ-FRESNEDO G, RUIZ JC, et al: Assessment of
glomerular filtration rate in transplant recipients with severe renal
insufficiency by Nankivell, Modification of Diet in Renal Disease
(MDRD), and Cockroft-Gault equations. Transplant Proc 35:1671–
1672, 2003
32. GASPARI F, FERRARI S, STUCCHI N, et al: Performance of different
prediction equations for estimating renal function in kidney trans-
plantation. Am J Transplant 4:1826–1835, 2004
33. NATIONAL KIDNEY FOUNDATION: K/DOQI clinical practice guidelines
for chronic kidney disease: Evaluation, classification, and stratifica-
tion. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis
39:S1–246, 2002
34. HIKI Y, LEONG S-Y, MATHEW TH, et al: Typing of intraglomerular
mononuclear cells associated with transplant glomerular rejection.
Clin Nephrol 26:244–249, 1986
35. BISHOP GA, HALL BM, DUGGIN GG, et al: Immunopathology of
renal allograft rejection analyzed with monoclonal antibodies to
mononuclear cell markers. Kidney Int 29:708–717, 1986
36. MAGIL AB: Infiltrating cell types in transplant glomerulitis: Rela-
tionship to peritubular capillary C4d deposition. Am J Kidney Dis
45:1084–1089, 2005
37. YANAGISAWA T, OTSUBO O, SHIMADA T, et al: Relationship between
macrophage infiltration of renal allografts and chronic renal impair-
ment. Transplant Proc 29:2783–2786, 1997
38. OJO AO, WOLFE RA, HELD PJ, et al: Delayed graft function: Risk
factors and implications for renal allograft survival. Transplantation
63:968–974, 1997
39. KONING OH, PLOEG RJ, VAN BOCKEL JH, et al: Risk factors for de-
layed graft function in cadaveric kidney transplantation: A prospec-
tive study of renal function and graft survival after preservation with
University of Wisconsin solution in multi-organ donors. European
Multicenter Study Group. Transplantation 63:1620–1628, 1997
40. TAKEMOTO S, TERASAKI PI, CECKA JM, et al: Survival of nationally
shared, HLA-matched kidney transplants from cadaveric donors.
The UNOS Scientific Renal Transplant Registry. N Engl J Med
327:834–839, 1992
41. HELD PJ, KAHAN BD, HUNSICKER LG, et al: The impact of HLA
mismatches on the survival of first cadaveric kidney transplants. N
Engl J Med 331:765–770, 1994
